<DOC>
	<DOCNO>NCT02913612</DOCNO>
	<brief_summary>Multi-center , double-masked randomize , efficacy , safety pharmacokinetic ( PK ) study .</brief_summary>
	<brief_title>Efficacy , Safety Pharmacokinetics Topical Timolol Infants With Infantile Hemangioma ( IH )</brief_title>
	<detailed_description>Primary : Describe efficacy 0.25 % 0.5 % topical timolol maleate GFS assess IH change color . Secondary : Describe safety PK topical timolol maleate GFS treatment IH .</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Inclusion Criteria 1 . Documented informed consent legal guardian 2 . 060 day postnatal age time first study dose enrol nonintervention cohort . 3 . Clinical diagnosis superficial cutaneous mucosal infantile hemangioma ( must include follow ) : a. Superficial lesion dermis b . Thin &lt; 2 mm thickness c. Small &lt; 5 cm2 d. Involves skin keratinize mucosa Exclusion Criteria 1 . History previous treatment pharmacologic laser therapy IH 2 . Ongoing therapy oral beta blocker oral corticosteroid unrelated condition ( e.g. , cardiac arrhythmia , adrenal insufficiency , upper airway obstruction , tetralogy fallot ( TOF ) , hypertension , reactive airway disease ) 3 . IH require systemic therapy ( defined dynamic complication scale &gt; 3 ) 4 . IH nonkeratinized mucosa 5 . Infants one hemangioma require therapy 6 . Hemodynamically significant cardiovascular disease , determine investigator 7 . Known allergy beta blocker vehicle 8 . Heart rate &lt; 100 beat per minute screen visit 9 . Known prenatal postnatal diagnosis 2nd/3rd degree atrioventricular block 10 . History Reactive Airways Disease ( RAD ) 11 . Any condition would make participant , opinion investigator unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Days</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hemangioma</keyword>
	<keyword>Infantile Hemangioma</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>